bioAffinity Technologies Restores Nasdaq Compliance, Strengthening Path Toward Long-Term Growth bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company dedicated to advancing early-stage cancer diagnostics, announced that it has successfully regained compliance with all Nasdaq Capital Market continued listing requirements.…
Viatris Expands CNS Portfolio in Japan with Acquisition of Aculys Pharma, Gaining Exclusive Rights to Pitolisant and Spydia® Viatris Inc. (Nasdaq: VTRS), a leading global healthcare company, today announced the successful acquisition of Aculys Pharma, Inc., a clinical-stage biopharmaceutical company…
argenx to Present Comprehensive Immunology Data at 2025 AANEM Annual Meeting and MGFA Scientific Session argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to improving the lives of people with severe autoimmune diseases, will present a wide…
Sanofi Establishes Montpellier as the Global Hub for Translational Research in Autoimmune Diseases Sanofi has announced the launch of a Translational Center of Excellence in Montpellier, a first-of-its-kind initiative developed in close partnership with the Immun4Cure University Hospital Institute (IHU…
Merck Presents New Phase 3 Data on Investigational Two-Drug HIV Regimen Doravirine/Islatravir (DOR/ISL) Showing Minimal Impact on Weight, Body Composition, and Lipid Levels Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced new results from its Phase…
AbbVie Announces FDA Approval of Updated RINVOQ® (upadacitinib) Indication for Inflammatory Bowel Disease NORTH CHICAGO, Ill., Oct. 13, 2025 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug…
Neurology Publication Demonstrates 95% Reduction in Mortality Risk with Pyrimidine Nucleos(t)ide Therapy in Patients with Thymidine Kinase 2 Deficiency (TK2d) UCB, a global biopharmaceutical company focused on the discovery and development of innovative treatments for serious diseases, today announced the…
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA, Set to Participate in Project Orbis BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)…
Zai Lab to Present Updated Phase 1 Data on DLL3-Targeted ADC Zocilurtatug Pelitecan (ZL-1310) at the 2025 AACR-NCI-EORTC International Conference Zai Lab Limited announced that new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug pelitecan (zoci), formerly…
AskBio Reports Interim Safety Data from Phase 1/2 LION-CS101 Trial of AB-1003 in Limb-Girdle Muscular Dystrophy 2I/R9 AskBio Inc. (AskBio), a gene therapy company wholly owned by Bayer AG and operated independently, today announced that it will present initial safety…
Satellos Bioscience Reports Promising Safety, Tolerability, and Functional Benefits of SAT-3247 in Adults with Duchenne Muscular Dystrophy Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a clinical-stage biotechnology company focused on developing transformative therapies for degenerative muscle diseases, has unveiled new…
Vividion Publishes Groundbreaking Science Study on Covalent RAS-PI3Kα Inhibitors That Halt Tumor Growth Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company and wholly owned, independently operated subsidiary of Bayer AG, has announced the publication of a pivotal manuscript in Science…